Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study
Conclusion:
Treatment with OM/AM/HCTZ achieved superior (SBP) ABPM reductions compared with mono, dual or triple drug therapy, resulting in all patients achieving systolic ABPM goal without ABPM documented hypotension.
Source: Therapeutic Advances in Cardiovascular Disease - Category: Cardiology Authors: Punzi, H. A. Tags: Original Research Source Type: research
More News: Benicar | Cardiology | Cardiovascular | Heart | Hydrochlorothiazide | Hypertension | Norvasc | Study